Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H10O4 |
Molecular Weight | 146.1412 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12OC[C@@H](O)[C@@]1([H])OC[C@@H]2O
InChI
InChIKey=KLDXJTOLSGUMSJ-JGWLITMVSA-N
InChI=1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/4952594
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4952594
Isosorbide is an effective hyperosmotic agent which can be administered orally without gastrointestinal irritation. It is absorbed quantitatively and more than 95% of the administered dose is excreted unchanged in the urine. Oral administration of a 50% solution to rabbits or man results in prompt increases in osmolarity of the serum and profound decreases in intraocular pressure. The drug proves useful in acute primary and secondary glaucomas, and as preoperative medication for various surgical procedures including cataract extraction, retinal detachment, corneal transplant, and glaucoma operations.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ISMOTIC Approved UseIsosorbide Mononitrate Extended-Release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1974 |
|||
Palliative | ISMOTIC Approved UseIsosorbide Mononitrate Extended-Release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1974 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.16 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4695381/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4695381/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Life threatening coronary artery spasm in childhood Kimura's disease. | 2000 Aug |
|
Pharmacological modulation of human gastric volumes demonstrated noninvasively using SPECT imaging. | 2001 Dec |
|
Potentiating potassium nitrate's desensitization with dimethyl isosorbide. | 2001 Sep-Oct |
|
A long-term transdermal nitric oxide donor improves uteroplacental circulation in women with preeclampsia. | 2002 Aug |
|
Coronary artery spasm associated with a moderately severe atherosclerotic stenosis in the proximal LAD. | 2002 Dec |
|
[Pulmonary hypertension and pregnancy]. | 2002 Feb |
|
Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. | 2002 May |
|
Nadolol and isosorbide prevented recurrent variceal bleeding better than did endoscopic ligation in cirrhosis. | 2002 May-Jun |
|
Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate. | 2002 Sep |
|
Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. | 2002 Sep 4 |
|
[Therapy with NO donors-antiatherogenic and antioxidant actions]. | 2004 Feb |
|
Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. | 2004 Summer |
|
Isosorbide delays gentamicin-induced vestibular sensory cell death. | 2005 |
|
Synthesis and structure activity relationships (SAR) of a new class of potent and selective butyrylcholinesterase inhibitors. | 2005 Dec 15 |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Hydrogen peroxide overload increases adriamycin-induced apoptosis of SaOS(2)FM, a manganese superoxide dismutase-overexpressing human osteosarcoma cell line. | 2005 May |
|
[Usefulness of sublingual isosorbide to assess the reversibility of pulmonary hypertension in cardiac transplant candidates]. | 2006 Feb |
|
Effects of simple and complex motion patterns on gene expression of chondrocytes seeded in 3D scaffolds. | 2006 Nov |
|
Vestibular evoked myogenic potentials in acute acoustic trauma. | 2006 Oct |
|
[Prevention of variceal bleeding and measurement of hepatic vein pressure gradient]. | 2006 Sep |
|
High performance liquid chromatography-electrospray ionization mass spectrometric determination of isosorbide 5-mononitrate in human plasma. | 2007 Feb 1 |
|
Occlusal management for a patient with aural symptoms of unknown etiology: a case report. | 2007 Sep 12 |
|
Physicochemical characterisation of a novel thermogelling formulation for percutaneous penetration of 5-aminolevulinic acid. | 2008 Jun |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
211-492-3
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
6057
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
1352008
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200660
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
m6540
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
ISOSORBIDE
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
DTXSID5046196
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
40725
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
652-67-5
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
3105
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
D007547
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
WXR179L51S
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
100000082855
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
12597
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
1501
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
SUB08334MIG
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
6433
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
C60773
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
DB09401
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY | |||
|
WXR179L51S
Created by
admin on Fri Dec 15 15:16:19 GMT 2023 , Edited by admin on Fri Dec 15 15:16:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY